Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Monday, April 3, 2023

Information

Tags:

ANN, Esperies, Health, ESPR, Patient, Conference, Risk, Broadcasting, Pharmaceutical industry

Geotags:

ANN ARBOR, MI, US

⚠ partially generated by AI ↴

Organisation:

ESPERION THERAPEUTICS, ESPERION THERAPEUTICS, INC.

Summary

Key Points:

ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET.
A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com.
Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22^nd Annual Virtual Healthcare Conference on Monday, April 17^th, 2023 at 8:45 AM ET.

To register for the live webcast, follow this link.

A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

ESPERION Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Contact:
Corporate Communications
[email protected]